Immune cell vaccine plus chemotherapy for advanced ovarian cancer

Plain-English translation of NCT05773859 on ClinicalTrials.gov ↗ · Source last updated November 2025 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new approach to treat advanced ovarian cancer by combining standard chemotherapy and surgery with specialized dendritic cell vaccinations. The vaccine uses your own tumor cells to train your immune system to recognize and fight cancer more effectively. Researchers hope this combination will improve outcomes for patients with advanced epithelial ovarian cancer.

Ovarian cancer remains very difficult to treat, with survival rates that haven't improved much over the past 20 years. This new treatment aims to fill that gap by harnessing your body's immune system to attack the cancer in a way that standard treatments alone cannot achieve.

Do you qualify?

You likely qualify if…

you are a woman over 18 years old
you have been diagnosed with advanced epithelial ovarian cancer (stage III or IV) that cannot be surgically removed initially
you have high-grade or low-grade serous ovarian cancer
you are healthy enough to tolerate chemotherapy and surgery, with good blood counts and organ function
you are able to commit to close monitoring of your immune system throughout the study

You likely don't qualify if…

you have had ovarian cancer before (recurrent disease)
you have a different type of ovarian cancer histology, such as endometrioid, mucinous, or clear cell
you have a serious heart condition or uncontrolled medical conditions that would make the vaccine unsafe
you have an active infection with hepatitis B, C, HIV, or syphilis
you have an autoimmune disease or are taking long-term immunosuppressive medications

What participation looks like

You will receive standard chemotherapy and surgery as usual, with the addition of specialized immune cell vaccinations timed during your treatment. The study involves regular blood tests and monitoring to track how your immune system responds to the vaccine. You'll be closely followed throughout the trial to ensure safety and to measure whether the vaccine helps your body fight the cancer more effectively.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(1 site)

Netherlands

Radboud University Medical Center, Nijmegen, Gelderland